Tags

Type your tag names separated by a space and hit enter

Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes.
Pediatr Res. 2009 Feb; 65(2):236-41.PR

Abstract

To investigate the possible effect of fetal exposure to selective serotonin reuptake inhibitors (SSRIs) on somatic growth and on hormones of the hypothalamic-pituitary-adrenal (HPA) and insulin-like growth factor (IGF)-I axes, we compared the anthropometric parameters and hormonal profile of 21 SSRI-exposed infants and 20 matched controls. The SSRI group was characterized by lower crown-heel length (p < 0.01), smaller head circumference (p = 0.08), and higher percentage of infants with birth weight, birth length, and head circumference below the 10th percentile (p < 0.045, p = 0.08, p < 0.04, respectively), in addition to a significantly lower cord blood level of cortisol (p < 0.03) and higher level of thyroid-stimulating hormone (TSH) (p < 0.004). Infants exposed to citalopram had a lower cord blood IGF-I level than infants exposed to paroxetine (p < 0.001) and controls (p < 0.003). Placental IGF-I receptor (IGF-IR) expression was significantly higher in the SSRI group than in controls (p < 0.01). Urine 5-hydroxyindoleacetic acid (5-HIAA) level was negatively correlated with birth weight (r = -0.71, p < 0.025) and with dehydroepiandrosterone (DHEA) level (r = -0.71, p < 0.025). The Finnegan score was correlated with dehydroepiandrosterone sulfate (DHEAS) (r = 0.8, p < 0.005) and cortisol (r = 0.62, p = 0.05). Fetal exposure to SSRIs causes impaired intrauterine growth accompanied by alterations in the IGF-I and HPA axes. The findings may raise concern regarding maternal use of SSRIs during pregnancy.

Authors+Show Affiliations

Department of Neonatology, Helen Schneider Hospital for Women, Rabin Medical Center, Petah Tiqwa 49100, Israel. shmueld@clalit.org.ilNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19262294

Citation

Davidson, Shmuel, et al. "Effect of Exposure to Selective Serotonin Reuptake Inhibitors in Utero On Fetal Growth: Potential Role for the IGF-I and HPA Axes." Pediatric Research, vol. 65, no. 2, 2009, pp. 236-41.
Davidson S, Prokonov D, Taler M, et al. Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatr Res. 2009;65(2):236-41.
Davidson, S., Prokonov, D., Taler, M., Maayan, R., Harell, D., Gil-Ad, I., & Weizman, A. (2009). Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatric Research, 65(2), 236-41. https://doi.org/10.1203/PDR.0b013e318193594a
Davidson S, et al. Effect of Exposure to Selective Serotonin Reuptake Inhibitors in Utero On Fetal Growth: Potential Role for the IGF-I and HPA Axes. Pediatr Res. 2009;65(2):236-41. PubMed PMID: 19262294.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes. AU - Davidson,Shmuel, AU - Prokonov,Diana, AU - Taler,Michal, AU - Maayan,Rachel, AU - Harell,Daniella, AU - Gil-Ad,Irit, AU - Weizman,Abraham, PY - 2009/3/6/entrez PY - 2009/3/6/pubmed PY - 2009/5/1/medline SP - 236 EP - 41 JF - Pediatric research JO - Pediatr Res VL - 65 IS - 2 N2 - To investigate the possible effect of fetal exposure to selective serotonin reuptake inhibitors (SSRIs) on somatic growth and on hormones of the hypothalamic-pituitary-adrenal (HPA) and insulin-like growth factor (IGF)-I axes, we compared the anthropometric parameters and hormonal profile of 21 SSRI-exposed infants and 20 matched controls. The SSRI group was characterized by lower crown-heel length (p < 0.01), smaller head circumference (p = 0.08), and higher percentage of infants with birth weight, birth length, and head circumference below the 10th percentile (p < 0.045, p = 0.08, p < 0.04, respectively), in addition to a significantly lower cord blood level of cortisol (p < 0.03) and higher level of thyroid-stimulating hormone (TSH) (p < 0.004). Infants exposed to citalopram had a lower cord blood IGF-I level than infants exposed to paroxetine (p < 0.001) and controls (p < 0.003). Placental IGF-I receptor (IGF-IR) expression was significantly higher in the SSRI group than in controls (p < 0.01). Urine 5-hydroxyindoleacetic acid (5-HIAA) level was negatively correlated with birth weight (r = -0.71, p < 0.025) and with dehydroepiandrosterone (DHEA) level (r = -0.71, p < 0.025). The Finnegan score was correlated with dehydroepiandrosterone sulfate (DHEAS) (r = 0.8, p < 0.005) and cortisol (r = 0.62, p = 0.05). Fetal exposure to SSRIs causes impaired intrauterine growth accompanied by alterations in the IGF-I and HPA axes. The findings may raise concern regarding maternal use of SSRIs during pregnancy. SN - 1530-0447 UR - https://www.unboundmedicine.com/medline/citation/19262294/Effect_of_exposure_to_selective_serotonin_reuptake_inhibitors_in_utero_on_fetal_growth:_potential_role_for_the_IGF_I_and_HPA_axes_ L2 - https://doi.org/10.1203/PDR.0b013e318193594a DB - PRIME DP - Unbound Medicine ER -